Pharmacotherapy of Drugs used in Multiple Sclerosis.

A tétel rövid nézete
dc.contributor.advisorMegyeri, Attila
dc.contributor.advisordeptDebreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézethu_HU
dc.contributor.authorJacks, Ibiye
dc.contributor.departmentDE--Általános Orvostudományi Karhu_HU
dc.contributor.opponentPórszász, Róbert
dc.contributor.opponentDrimba, László
dc.contributor.opponentdeptDebreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézethu_HU
dc.contributor.opponentdeptKenézy Kórház Központi Aneszteziológiai és Intezív Terápiás Osztályhu_HU
dc.date.accessioned2020-02-24T11:04:22Z
dc.date.available2020-02-24T11:04:22Z
dc.date.created2019-03-12
dc.description.abstractMultiple sclerosis (MS) is currently one of the main causes of disability in the young and currently has no cure till date. There have been advances in the therapeutic options for patients with multiple sclerosis. Treatment is aimed at disease modifying and symptoms management. Glatiramer and interferons are the first line drugs used for the treatment. Both drugs alter the short-term course of MS. Currently disease modifying therapies (DMTs) are available for mostly relapsing forms of MS. They decrease the clinical episodes of inflammation, new magnetic resonance imaging (MRI) lesions and decrease the progression of disability. Accurate diagnosis helps in proper approach to treatment and it relies on a combination of clinical history, neurological examination and paraclinical testing such as MRI and sometimes cerebrospinal fluid analysis.hu_HU
dc.description.courseáltalános orvoshu_HU
dc.description.courselangangolhu_HU
dc.description.degreeegységes, osztatlanhu_HU
dc.format.extent29hu_HU
dc.identifier.urihttp://hdl.handle.net/2437/281207
dc.language.isoenhu_HU
dc.subjectMultiple Sclerosishu_HU
dc.subject.dspaceDEENK Témalista::Orvostudományhu_HU
dc.titlePharmacotherapy of Drugs used in Multiple Sclerosis.hu_HU
Fájlok
Gyűjtemények
Theses (Faculty of Medicine)